**ORIGINAL RESEARCH**

**Frequency and intensity of $^{[18F]}$-PSMA-1007 uptake after COVID-19 vaccination in clinical PET**

**Objectives:** To assess the frequency and intensity of $^{[18F]}$-prostate-specific membrane antigen (PSMA)-1007 axillary uptake in lymph nodes ipsilateral to COVID-19 vaccination with BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) in patients with prostate cancer referred for oncological $^{[18F]}$-PSMA positron emission tomography (PET)/CT or PET/MR imaging.

**Methods:** 126 patients undergoing $^{[18F]}$-PSMA PET/CT or PET/MR imaging were retrospectively included. $^{[18F]}$-PSMA activity (maximum standardized uptake value) of ipsilateral axillary lymph nodes was measured and compared with the non-vaccinated contralateral side and with a non-vaccinated control group. $^{[18F]}$-PSMA active lymph node metastases were measured to serve as quantitative reference.

**Results:** There was a significant difference in maximum standardized uptake value in ipsilateral and compared to contralateral axillary lymph nodes in the vaccination group ($n = 63, p = 0.379$). Vaccinated patients showed mildly increased axillary lymph node $^{[18F]}$-PSMA uptake as compared to non-vaccinated patients ($p = 0.03$). $^{[18F]}$-PSMA activity of lymph node metastases was significantly higher ($p < 0.001$) compared to axillary lymph nodes of vaccinated patients.

**Conclusion:** Our data suggest mildly increased $^{[18F]}$-PSMA uptake after COVID-19 vaccination in ipsilateral axillary lymph nodes. However, given the significantly higher $^{[18F]}$-PSMA activity of lymph node metastases compared to “reactive” nodes after COVID-19 vaccination, no therapeutic and diagnostic dilemma is to be expected.

**Advances in knowledge:** No specific preparations or precautions (e.g. adaption of vaccination scheduling) need to be undertaken in patients undergoing $^{[18F]}$-PSMA PET imaging after COVID-19 vaccination.

**INTRODUCTION**

The COVID-19 pandemic still deeply affects healthcare systems worldwide. The harmful effect the virus exerts is a major concern for global health, particularly in elderly patients or patients with malignant tumors. Among the latter, the fatality rate was reported to be higher even after adjusting for confounders. This is why patients with malignant diseases were prioritized to receive COVID-19 vaccinations. Swelling and pain at the injection site as well as ipsilateral axillary lymphadenopathy were acknowledged as side-effects of COVID-19 vaccines.

Numerous studies reported metabolically active axillary lymph nodes after $^{[18F]}$-fludeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT), sometimes with relevant clinical impacts such as unnecessary lymph node core needle biopsy. Therefore, different expert consensus statements for the management of axillary lymph adenopathy in patients with prior COVID-19 vaccination undergoing imaging were published. However, previous studies were mainly focused on $^{[18F]}$-FDG-imaging and evidence is sparse with regard to the potential effect of COVID-19 vaccination in prostate-specific membrane antigen $^{[18F]}$-PSMA-1007 imaging.

Accordingly, the purpose of this study was to analyze the overall frequency and intensity of $^{[18F]}$-PSMA avid axillary
PET data analysis

One reader (A.M., 6 years of experience in radiology, and 3 years of experience in PET imaging) reviewed all PET data sets. Commercial image analysis software (Advantage Workstation v. 4.7, GE Healthcare) was used for review. The reader measured $^{[18F]}$-PSMA avidity by drawing a semi-automated cubic volume of interest (VOI) around the most avid axillary lymph nodes bilaterally. $^{[18F]}$-PSMA avidity was measured as the maximum standardized uptake value (SUV$_{max}$) within the VOI (i.e. decay corrected radioactivity per volume [kBq/ml], divided by the initially injected dose [MBq] and multiplied by body weight [kg]). The absolute difference in SUV$_{max}$ between the data pairs of axillary lymph nodes was calculated for the vaccinated group. A positive reaction was defined as unilateral $^{[18F]}$-PSMA avidity of axillary lymph nodes ipsilateral to the prior vaccination site having a difference in SUV$_{max}$ of >1.0 (avidity ipsilateral lymph nodes - avidity contralateral lymph node), as previously described.\(^5\)

SUV$_{max}$ of ipsilateral and contralateral axillary lymph nodes in the vaccinated group and SUV$_{max}$ of right and left axillary lymph nodes in the non-vaccinated group were compared. Further, we reviewed all clinical reports, and SUV$_{max}$ of up to three $^{[18F]}$-PSMA avid lymph node metastases were measured to serve as quantitative reference. SUV$_{max}$ of left axillary lymph nodes in the non-vaccinated group served as a negative control.

Statistical analysis

All statistical analyses were performed in the open-source statistics software R (v. 3.6.1, R Foundation for Statistical Computing, Vienna, Austria). Categorical variables are expressed as frequency distribution. Continuous variables are presented as mean ± standard deviation if normally distributed, or median (range) otherwise. Assessment of group differences was determined using t-test (paired or unpaired) after ensuring a normal distribution of the data using the Shapiro–Wilk test, and normality was rejected if p < 0.05. For non-normally distributed data, Wilcoxon-test or Mann–Whitney test was used. Categorical data were compared using χ² test. For all comparisons, a two-tailed p-value of <0.05 was considered to be statistically significant.

RESULTS

Patient characteristics and clinical information

126 patients undergoing $^{[18F]}$-PSMA-1007 PET/CT (73/126, 58%) or PET/MR imaging (53/126, 42%) for staging or restaging of prostate cancer were retrospectively included in the study, see Table 1. 29 of the 63 vaccinated patients (44%) had received Pfizer-BioNTech and 34 (56%) Moderna vaccines. 11 of 63 patients (17%) were vaccinated for the first time, and 52 of 63 patients (83%) had been vaccinated two times.

$^{[18F]}$-PSMA AVIDITY OF AXILLARY LYMPH NODES IPSILATERAL TO COVID-19 VACCINATION SITE

Overall, there were 12/63 (19%) patients presenting with $^{[18F]}$-PSMA avid lymph nodes ipsilateral to the vaccine injection site (SUV$_{max}$ range, 1.9–6.9). Frequency of patients with $^{[18F]}$-PSMA active ipsilateral lymph nodes after COVID-19 vaccination with regard to time after vaccination are presented in Table 2.
correlation showed a negative, albeit not significant correlation of day after COVID-19 vaccination and SUV\textsubscript{max} of ipsilateral lymph nodes (first vaccination: $R = -0.18$, $p = 0.580$, second vaccination: $R = -0.18$, $p = 0.217$, overall: $R = -0.13$, $p = 0.297$), Figure 2.

Table 1. Demographic data of study subjects ($n = 126$)

| Age, years       | 71 ± 8 (53–87) |
|------------------|----------------|
| Body weight, kg  | 82 ± 12 (54 – 115) |
| Body height, m   | 1.76 ± 0.07 (1.52 – 1.89) |
| BMI, kg/m\(^2\)  | 26.6 ± 3.6 (19.2 – 34.9) |
| PSA values, ng/ml| 2.9 (IQR 0.59 – 9.91) |

| Indication for imaging | | |
|------------------------|------------------|------------------|
| Staging                | 36 (29%)         |
| Early BCR              | 37 (30%)         |
| Tumor burden evaluation| 52 (41%)         |

| Initial T classification | | |
|--------------------------|------------------|------------------|
| T1                       | 21 (22%)         |
| T2                       | 34 (35%)         |
| T3                       | 39 (41%)         |
| T4                       | 2 (2%)           |

| Initial N classification | | |
|--------------------------|------------------|------------------|
| N0                       | 110 (87%)        |
| N1                       | 16 (13%)         |

| Initial M classification | | |
|--------------------------|------------------|------------------|
| M0                       | 115 (91%)        |
| M1                       | 11 (9%)          |

| IQR interquartile range; BCR, biochemical recurrence; BMI, Body mass index; MBq, Mega-Becquerel; PET/CT, positron emission tomography/computed tomography; PET/MRI, positron emission tomography/magnet resonance imaging. Values are given as absolute numbers and percentages in parenthesis or mean ± standard deviation (range) or median (interquartile range). |

Table 2. Frequency of patients with \([^{18}F]\)-PSMA-1007-active\(^a\) ipsilateral lymph nodes after COVID-19 vaccination with regard to time delay between vaccination and PET scan

| Days after COVID-19 vaccination | Increased \([^{18}F]\)-PSMA-1007 uptake in axillary lymph node | | |
|--------------------------------|----------------------------------------------------------|------------------|------------------|
|                                 | Total patients | Yes | No | SUV\textsubscript{max} |
| Overall                        | 63 (100%)      | 12 (17%) | 51 (83%) | 3.5 (1.9 – 6.5) |
| Day 0–14                       | 13 (21%)       | 2 (15%) | 11 (85%) | 3.1 (2.3 – 3.8) |
| Day 15–28                      | 8 (13%)        | 1 (12%) | 7 (88%) | 3.2 (3.2) |
| Day 29–50                      | 12 (19%)       | 3 (25%) | 9 (75%) | 3.1 (2.4 – 4.1) |
| Day 51–100                     | 19 (30%)       | 4 (21%) | 15 (79%) | 4.0 (1.9 – 6.5) |
| Day >100                       | 11 (17%)       | 2 (18%) | 9 (82%) | 3.7 (2.4 – 4.9) |

PET, positron emission tomography; SUV\textsubscript{max}, Maximum standardized uptake value. Values are given as absolute numbers and percentages in parenthesis or mean (range). \(^a\)i.e. defined as unilateral PSMA-activity of axillary lymph nodes ipsilateral to prior vaccination having a difference in SUV\textsubscript{max}>1.0 (avidity ipsilateral lymph nodes - avidity contralateral lymph node).

**QUANTITATIVE COMPARISON OF NON-VACCINATED VS. VACCINATED PATIENTS AND \([^{18}F]\)-PSMA AVID LYMPH NODE METASTASES**

There was a significant difference in SUV\textsubscript{max} in ipsilateral and contralateral axillary lymph nodes in the vaccinated group, $p < 0.001$. No difference in SUV\textsubscript{max} in left and right axillary lymph node in the non-vaccinated control group was detected, $p = 0.379$.

The mean \([^{18}F]\)-PSMA uptake in left axillary lymph nodes of non-vaccinated patients was SUV\textsubscript{max} 1.8 ± 0.7 (range, 0.4 to 3.8). Vaccinated patients showed mildly increased \([^{18}F]\)-PSMA uptake.
in the ipsilateral lymph nodes compared to non-vaccinated patients, with a mean SUV$_{\text{max}}$ of 2.2 ± 1.0 (range, 0.6–5.2); \( p = 0.03 \). Comparing activity of $^{18}$F-PSMA avid lymph node metastases \( (n = 75) \) with axillary lymph nodes of vaccinated patients, we observed a significantly higher $^{18}$F-PSMA uptake of lymph node metastases, with a median SUV$_{\text{max}}$ of 13.3 (range, 6.8–21.3), \( p < 0.001 \), Figure 3.

A representative case of PET/CT with $^{18}$F-PSMA avid axillary lymphadenopathy is given in Figure 4.

**DISCUSSION**

In this retrospective cohort study, we sought to assess frequency and intensity of axillary lymph node $^{18}$F-PSMA-1007 uptake ipsilateral to COVID-19 vaccination in patients with prostate cancer undergoing PET.

The main findings of the study were as follows: first, there was mildly increased $^{18}$F-PSMA uptake in ipsilateral lymph nodes after COVID-19 vaccination in comparison to the non-vaccinated control cohort. Second, $^{18}$F-PSMA positive prostatic lymph node metastases had significantly higher $^{18}$F-PSMA uptake than axillary lymph nodes after COVID-19 vaccination.

In contrast to our study, the recent work published by Eifer et al did not show a difference in $^{18}$F-PSMA uptake in ipsilateral lymph nodes after COVID-19 vaccination.\(^8\) One possible explanation for this discrepancy may be that Eifer et al used two different radiotracers $^{[18]}$F-PSMA and $^{[68]}$Ga-PSMA in their study. To that regard, Rauscher et al demonstrated higher unspecific uptake in lymph nodes in $^{[18]}$F-PSMA-1007 PET, the tracer used in our study, compared to $^{[68]}$Ga-PSMA-11 PET.\(^9\) Further, a different study design using an SUV$_{\text{max}}$ cut-off ratio of ≥1.5 in ipsilateral vs contralateral lymph nodes for defining positive lymph nodes lowers the frequency of “positive findings”.\(^8\)

The mechanism of $^{[18]}$F-PSMA expression and/or $^{[18]}$F-PSMA ligand accumulation in inflammatory and infectious processes is not well understood, and only a few studies on this topic are available.\(^10\) There is some evidence that increased $^{[18]}$F-PSMA expression during neovascularization,\(^11\) accumulation of $^{[18]}$F-PSMA ligands at the infection site,\(^10\) and the interference of macrophage folate receptors with $^{[18]}$F-PSMA ligands\(^12\) may play a role in inflammatory and infectious processes.

Pelvic and retroperitoneal lymph nodes are the most common site for nodal prostate cancer metastases.\(^13\) In advanced disease, however, thoracic and cervical lymph nodes may be involved as well.\(^13\) Axillary lymph node metastases from prostate cancer are extremely rare, yet a few cases have been described in literature.\(^13\)–\(^15\) Therefore, increased $^{[18]}$F-PSMA uptake in axillary lymph nodes after COVID-19 vaccination bears little impact in clinical routine, especially as lymph node metastases of prostate carcinoma show significantly higher $^{[18]}$F-PSMA ligand accumulation than axillary lymph nodes after COVID-19 vaccination, as observed in our study. In contrast, Skawran et al demonstrated metabolically active axillary lymph nodes in $^{[18]}$F-FDG PET after COVID-19 vaccination leading to diagnostic and therapeutic dilemmas.\(^5\)

We are aware of some noteworthy limitations: first, our study population is rather small. Second, no pathological confirmation of the inflammatory state of axillary lymph nodes after COVID-19
vaccination was available, further yielding the potential bias of additional different pathologies and/or haematological disorder. Third, there is no follow-up imaging to assess the persistence of $^{18}$F-PSMA uptake. Fourth, because of the relatively small study population, no subanalysis for the two used vaccines BNT162b2 and mRNA-1273 and for the different scanner types (PET/CT or PET/MR) was performed. Fourth, we did not include patients after third (i.e. booster) vaccinations, which may also differently impact lymph node activity. Fifth, we did not measure additional reference tissue and/or different sites of reactive PSMA-uptake which may serve in future studies as an additional quantitative comparison.

**CONCLUSIONS**

Our data suggest (mildly) increased $^{18}$F-PSMA uptake after COVID-19 vaccination in ipsilateral axillary lymph nodes - possibly owing to reactive inflammatory changes. Given the significantly higher $^{18}$F-PSMA uptake of prostatic cancer lymph node metastases compared to ‘reactive’ nodes after COVID-19 vaccination and the overall sparsity of axillary prostate cancer lymph node metastases, no therapeutic and diagnostic dilemma is to be expected.

**ACKNOWLEDGMENT**

Dr Stephan Skawran is supported by a grant form the Palatin-Foundation, Switzerland. Dr Michael Messerli and Dr Irene Burger received a research grant from the Ien-Kohaut Foundation, Switzerland. Dr Michael Messerli and Dr Huellner are supported by a grant from the CRPP AI Oncological Imaging Network of the University of Zurich. Dr Martin W. Huellner received grants from GE Healthcare and a fund by the Alfred and Annemarie von Sick legacy for translational and clinical cardiac and oncological research. The authors would like to thank Freya Klein, Josephine Trinckaft, Corina Weyermann, Marlena Hofbauer, Victoria Schoder, Edlira Loga, Melanie Thüringer, Nina Bächle, Sabrina Epp, Ana-Mari Gaspar, Michèle Hug, Juliana Koller, Eirini Leivaditaki and Danijel Tomic for their excellent support. Further, Dr Michael Messerli would like to thank Prof G. K. von Schulthess for his invaluable support of this work.

**COMPETING INTERESTS**

The University Hospital of Zurich holds a research agreement with GE Healthcare (unrelated to current study). Other than that, the authors declare that they have no competing interests.

**REFERENCES**

1. Ribas A, Sengupta R, Locke T, Zaidi SK, Campbell KM, et al. Priority covid-19 vaccination for patients with cancer while vaccine supply is limited. *Cancer Discov* 2021; 11: 233–36. https://doi.org/10.1158/2159-8290.CD-20-1817
2. Baden LR, El Sahly HM, Essink B, Kotloff KL, Fenyö E, et al. Efficacy and safety of the mrna-1273 sars-cov-2 vaccine. *N Engl J Med* 2021; 384: 403–16. https://doi.org/10.1056/NEJMo2035389
3. Cohen D, Krauthammer SH, Wolf I, Even-Sapir E. Hypermetabolic lymphadenopathy following administration of bnt162b2 mrna covid-19 vaccine: incidence assessed by $^{18}$F-fdg pet ct and relevance to study interpretation. *Eur J Nucl Med Mol Imaging* 2021; 48: 1854–63. https://doi.org/10.1007/s00259-021-05314-2
4. Treglia G, Cuzzocrea M, Giovanella L, Elzi A, Velleri S. Prevalence and significance of hypermetabolic lymph nodes detected by $^{18}$F-fdg pet/ct after covid-19 vaccination: a systematic review and a meta-analysis. *Pharmaceuticals (Basel)* 2021; 14(8): 762. https://doi.org/10.3390/ph14080762
5. Skawran S, Gennari AG, Dittli M, Treyer V, Muehlematter UJ, et al. $^{18}$F-fdg uptake of axillary lymph nodes after covid-19 vaccination in oncological pet/ct: frequency, intensity, and potential clinical impact. *Eur Radiol* 2022; 32: 508–16. https://doi.org/10.1007/s00330-021-08122-2
6. Seely JM, Barry MH. The canadian society of breast imaging recommendations for the management of axillary adenopathy in patients with recent covid-19 vaccination - update. *Can Assoc Radiol J* 2021; 72: 601–2. https://doi.org/10.1177/0846537121998949
7. Messerli M, Libervini V, Grünig H, Maurer A, Skawran S, et al. Clinical evaluation of data-driven respiratory gating for pet/ct in an oncological cohort of 149 patients: impact on image quality and patient management. *Br J Radiol* 2021; 94(1126): 20201350. https://doi.org/10.1259/bjr.20201350
8. Eifer M, Tau N, Alhoubani Y, Kanana N, Domachevsky L, et al. COVID-19 mrna vaccination: age and immune status and its association with axillary lymph node pet/ct uptake. *J Nucl Med* 2022; 63: 134–39. https://doi.org/10.2967/jnumed.121.262194
9. Rauscher I, Krönke M, König M, Gafita A, Maurer T, et al. Matched-pair comparison of $^{68}$Ga-psma-11 pet/ct and $^{18}$F-psma-1007 pet/ct: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy. *J Nucl Med* 2020; 61: 51–57. https://doi.org/10.2967/jnumed.119.229187
10. de Galiza Barbosa F, Queiroz MA, Nunes RF, Costa LB, Zaniboni EC, et al. Nonprostatic diseases on psma pet imaging: a spectrum of benign and malignant findings. *Cancer Imaging* 2020; 20: 23. https://doi.org/10.1186/s40644-020-00300-7
11. O’Keefe DS, Bacich DJ, Huang SS, Heston WDW. A perspective on the evolving story of psma biology, psma-based imaging, and endoradiotherapeutic strategies. *J Nucl Med* 2018; 59: 1007–13. https://doi.org/10.2967/jnumed.117.203877
12. Hermann RM, Dnatinathan M, Czech N, Nitsche M. Prostate-specific membrane antigen pet/ct: false-positive results due to sarcoidosis? *Rep Pract Oncol Res* 2016; 9: 457–63. https://doi.org/10.1159/000447688
13. Barbosa FG, Queiroz MA, Nunes RF, Viana PCC, Marin JFG, et al. Revisiting prostate cancer recurrence with psma pet: atlas of typical and atypical patterns of spread. *Radiographics* 2019; 39: 186–212. https://doi.org/10.1148/rg.2019180079
14. Mreni A, Mbwanmo OJ, Bright F, Mbwanmo JS, Mzeta KA, et al. Left axillary lymphadenopathy as initial presentation of metastatic prostate cancer: a rare case report. *Int J Surg Case Rep* 2021; 82: S210-2612(21)30091-6: 105889. https://doi.org/10.1016/j.ijsr.2021.105889
15. Vinjamoori AH, Jagannathan JP, Shinagare BJ, Tao H, Hricak H, et al. Prevalence and significance of axillary lymph node pet/ct following administration of bnt162b2 mrna covid-19 vaccine: incidence assessed by $^{18}$F-fdg pet ct and relevance to study interpretation. *Eur J Nucl Med Mol Imaging* 2021; 48: 1854–63. https://doi.org/10.1007/s00259-021-05314-2